Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in metastatic androgen-independent prostate cancer
NCT00638378Phase 2Terminated
- Sponsor
- Incyte
- Start
- Feb 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Incyte. Started Feb 2008; status: terminated.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00638378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00638378.